hiEX™ Research iPSC Exosomes

Cat.-Nr.: ASXO-1003

Description

Uncover new biological insights with hiEX™ Research iPSC Exosomes— consistent and scalable extracellular vesicles (EVs). These exosomes are isolated from a single, well-characterized human iPSC line, ActiCells™ GMP-Matching RUO TARGATT™ hiPSCs (#AST-9450), which is grown using proprietary 3D culture conditions optimized for maintaining pluripotency. hiEX™ Research iPSC Exosomes are ideal for probing fundamental biological questions while laying the groundwork for therapeutic innovation.

Easily explore the power of iPSC exosomes for studies on wound healing, aging, nerve regeneration, and more.

  • Consistent and scalable—isolated from a single, well-characterized iPSC line rather than a mix of donors with different genetic backgrounds
  • Identity verified—every lot analyzed for tetraspanin surface markers (CD9, CD63, CD81), particle size, and concentration
  • Well-characterized—representative proteomic and miRNA data available upon request
  • Functional—shows dose-dependent activity in an in vitro wound healing assay
  • Customizable—isolated from iPSCs grown using our proprietary 3D culture methods, hiEX Research iPSC Exosomes can be custom-formulated to meet your project needs
  • Bulk pricing available—contact us for more information

Why exosomes?

As central players in cell-cell communication, exosomes can deliver miRNAs, proteins, and other biomolecules that influence cell fate, inflammation, repair, and regeneration1–3.

Why exosomes from iPSCs?

Emerging studies highlight the power of iPSC-derived exosomes to modulate key biological pathways and potentially treat disease1–3. They’ve been shown to enhance neuronal survival and axonal regeneration in spinal cord and nerve crush models4,5, lessen biomarkers of aging and senescence in human dermal fibroblasts6, reduce the vascular remodeling that is the hallmark of pulmonary arterial hypertension (PAH) in a rat model7, and promote wound healing8, including in corneal epithelial defects9. These are just a small sample of existing work, with additional studies being published every day.

Why hiEX™ Research iPSC Exosomes?

hiEX™ exosomes offer a clean and reproducible system for studying cellular physiology and disease treatments free from the donor variability and mixed genetic backgrounds that complicate primary cell-derived preparations like mesenchymal stem cells (MSCs).

Because hiEX™ exosomes are isolated from a cell line that has a TARGATT™ landing pad at the H11 safe harbor site, ActiCells™ GMP-Matching RUO TARGATT™ hiPSCs (#AST-9450), we can easily express one or more genes-of-interest in the parent cells for incorporation into exosomes. We can also differentiate the parent iPSCs into your desired cell type before isolating exosomes. To learn more about how we can customize your exosomes, visit our iPSC Exosome Services page or contact us.

Whether you’re exploring the fundamental roles of extracellular vesicles or laying the foundation for exosome-based therapeutics, hiEX™ Research iPSC Exosomes deliver the quality, flexibility, and scientific clarity your work demands.

About hiEX™ Research iPSC Exosomes

Every vial of hiEX™ Research iPSC Exosomes contains >10 x 109 extracellular vesicle (EV) particles isolated from human iPSCs in 1 mL of PBS (custom formulations available – contact us).

Each lot is rigorously characterized for identity and purity, including tetraspanin surface markers (CD9, CD63, CD81), particle size (typically 30 – 120 nm in diameter), and concentration.

We periodically perform mass spectrometry and RNAseq analysis on hiEX™ Exosomes and can confirm that they contain the expected exosome markers CD9, CD63, CD81, and TSG-101. hiEX™ Exosomes do not contain any Yamanaka reprogramming factors—OCT4, SOX2, c-MYC, and KLF4—indicating that they pose no risk for reprogramming exposed cells.

Representative proteomic and miRNA profiles are available upon request to support your mechanistic studies.

  • SUPPLIER:

    Applied StemCell

  • STATUS:

    In Stock

Overview

iPSC-derived Exosomes for research use only.
  • Species: Human
  • Features: male, TARGATT
  • Product Type: Exosomes
  • Storage:n -80°C freezer immediately upon receipt

Related Files

Datasheet

References

  1. Wang AYL. Human Induced Pluripotent Stem Cell-Derived Exosomes as a New Therapeutic Strategy for Various Diseases. Int J Mol Sci. 2021;22(4):1769. doi:10.3390/ijms22041769
  2. Germena G, Hinkel R. iPSCs and Exosomes: Partners in Crime Fighting Cardiovascular Diseases. J Pers Med. 2021;11(6):529. doi:10.3390/jpm11060529
  3. Jeske R, Bejoy J, Marzano M, Li Y. Human Pluripotent Stem Cell-Derived Extracellular Vesicles: Characteristics and Applications. Tissue Eng Part B Rev. 2020;26(2):129-144. doi:10.1089/ten.teb.2019.0252
  4. Aldali F, Yang Y, Deng C, et al. Induced Pluripotent Stem Cell-Derived Exosomes Promote Peripheral Nerve Regeneration in a Rat Sciatic Nerve Crush Injury Model: A Safety and Efficacy Study. Cells. 2025;14(7):529. doi:10.3390/cells14070529
  5. Abbas A, Huang X, Ullah A, et al. Enhanced spinal cord repair using bioengineered induced pluripotent stem cell-derived exosomes loaded with miRNA. Mol Med. 2024;30(1):168. doi:10.1186/s10020-024-00940-6
  6. Oh M, Lee J, Kim YJ, Rhee WJ, Park JH. Exosomes Derived from Human Induced Pluripotent Stem Cells Ameliorate the Aging of Skin Fibroblasts. Int J Mol Sci. 2018;19(6):1715. doi:10.3390/ijms19061715
  7. Chi PL, Cheng CC, Wang MT, et al. Induced pluripotent stem cell–derived exosomes attenuate vascular remodelling in pulmonary arterial hypertension by targeting HIF-1α and Runx2. Cardiovasc Res. 2024;120(2):203-214. doi:10.1093/cvr/cvad185
  8. Lu M, Peng L, Ming X, et al. Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts. eBioMedicine. 2019;42:443-457. doi:10.1016/j.ebiom.2019.03.011
  9. Wang S, Hou Y, Li X, et al. Comparison of exosomes derived from induced pluripotent stem cells and mesenchymal stem cells as therapeutic nanoparticles for treatment of corneal epithelial defects. Aging. 2020;12(19):19546-19562. doi:10.18632/aging.103904

RELATED PRODUCTS


ActiCells™ GMP-Matching RUO TARGATT™ hiPSC Knock-in KitSSEA4 DAPI Staining of Exosomes (20x)hiEx™ Research iPSC Exosome Services